Home › Companies › EVMN

Evommune, Inc.

EVMN Lead: Phase 2 1 Biotech Distilled article ↓

Dermatology Immunology Neurology Protein Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (6 active programs)

EVO756

Small Molecule Target: MRGPRX2

Chronic Spontaneous Urticaria Phase 2 oral
Chronic Inducible Urticaria Phase 2 oral
Atopic Dermatitis Phase 2 oral
Migraine oral

EVO301

Protein Target: IL-18

Atopic Dermatitis Phase 2 intravenous AprilBio
Ulcerative Colitis AprilBio

Biotech Distilled coverage (1)

2026-05-22 Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.